Company Aytu BioPharma, Inc.

Equities

AYTU

US0547548588

Pharmaceuticals

Market Closed - Nasdaq 04:30:00 2024-03-28 pm EDT 5-day change 1st Jan Change
3.04 USD -1.30% Intraday chart for Aytu BioPharma, Inc. +2.01% +7.04%

Business Summary

Aytu BioPharma, Inc. is a pharmaceutical company commercializing a portfolio of commercial prescription therapeutics and consumer health products. The Company’s Rx segment consists of prescription pharmaceutical products and the Consumer Health segment consists of various consumer healthcare products (the Consumer Health Portfolio). The Company’s prescription products include Adzenys XR-ODT (amphetamine) extended-release orally disintegrating tablets and Cotempla XR-ODT (methylphenidate) extended-release orally disintegrating tablets for the treatment of attention deficit hyperactivity disorder (ADHD); Karbinal ER (carbinoxamine maleate), an extended-release antihistamine suspension indicated to treat numerous allergic conditions; and Poly-Vi-Flor and Tri-Vi-Flor, two complementary fluoride-based prescription vitamin product lines available in various formulations for infants and children with fluoride deficiency. Its Consumer Health Segment addresses a range of common conditions.

Sales per Business

USD in Million2022Weight2023Weight Delta
Aytu Bioscience
68.7 %
61 63.2 % 74 68.7 % +20.74%
Aytu Consumer Health
31.3 %
36 36.8 % 34 31.3 % -5.48%

Sales per region

USD in Million2022Weight2023Weight Delta
United States
99.6 %
95 97.9 % 107 99.6 % +13.01%
International
0.4 %
2 2.1 % 0 0.4 % -76.68%

Managers

Managers TitleAgeSince
Chief Executive Officer 49 15-04-15
Founder 49 15-04-15
Director of Finance/CFO 55 22-01-16
Chief Operating Officer - 04-12-31
Chief Tech/Sci/R&D Officer - 20-12-31
Corporate Officer/Principal - -
General Counsel - 18-05-31
Corporate Officer/Principal 42 -
Human Resources Officer - 23-02-28

Members of the board

Members of the board TitleAgeSince
Director/Board Member 62 22-06-30
Founder 49 15-04-15
Chief Executive Officer 49 15-04-15
Director/Board Member 56 16-07-11
Director/Board Member 61 16-04-12
Director/Board Member 33 23-06-11

Share class

VoteQuantityFree-FloatCompany-owned sharesTotal Float
Stock A 1 5,567,597 5,373,596 ( 96.52 %) 0 96.52 %

Shareholders

NameEquities%Valuation
Nantahala Capital Management LLC
19.52 %
1,086,812 19.52 % 3 M $
Stonepine Capital Management LLC
8.486 %
472,469 8.486 % 1 M $
71,591 1.286 % 206 898 $
Renaissance Technologies LLC
1.238 %
68,923 1.238 % 199 187 $
58,357 1.048 % 168 652 $
Geode Capital Management LLC
0.5935 %
33,046 0.5935 % 95 503 $
Vanguard Group, Inc. (Subfiler)
0.4895 %
27,251 0.4895 % 78 755 $
BlackRock Institutional Trust Co. NA
0.4094 %
22,793 0.4094 % 65 872 $
22,560 0.4052 % 65 198 $
Acadian Asset Management LLC
0.2626 %
14,622 0.2626 % 42 258 $

Company contact information

Aytu Biopharma, Inc.

7900 East Union Avenue Suite 920

80237, Englewood

+720 437 6580

http://www.aytubio.com
address Aytu BioPharma, Inc.(AYTU)

Sales per Business

Sales per region

Trading Rating
Investor Rating
ESG Refinitiv
D
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
1
Last Close Price
3.04 USD
Average target price
8 USD
Spread / Average Target
+163.16%
Consensus